UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The host STING pathway at the interface of cancer and immunity

The Journal of clinical investigation, 2016-07, Vol.126 (7), p.2404-2411

2016

Volltextzugriff (PDF)

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Cell reports (Cambridge), 2015-05, Vol.11 (7), p.1018-1030

2015

Volltextzugriff (PDF)

SLC19A1 transports immunoreactive cyclic dinucleotides

Nature (London), 2019-09, Vol.573 (7774), p.434-438

2019

Volltextzugriff (PDF)

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Clinical cancer research, 2023-01, Vol.29 (1), p.110-121

2023

Volltextzugriff (PDF)

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Science translational medicine, 2015-04, Vol.7 (283), p.283ra52

2015

Volltextzugriff (PDF)

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA

The Journal of immunology (1950), 2016-04, Vol.196 (7), p.3191-3198

2016

Volltextzugriff (PDF)

Identification of host cytosolic sensors and bacterial factors regulating the type I interferon response to Legionella pneumophila

PLoS pathogens, 2009-11, Vol.5 (11), p.e1000665-e1000665

2009

Volltextzugriff (PDF)

Induction of type I interferons by bacteria

Cellular microbiology, 2010-07, Vol.12 (7), p.881-890

2010

Volltextzugriff (PDF)

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection

Cell reports (Cambridge), 2018-05, Vol.23 (5), p.1435-1447

2018

Volltextzugriff (PDF)

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

The Journal of experimental medicine, 2009-08, Vol.206 (9), p.1899-1911

2009

Volltextzugriff (PDF)

Interferon Regulatory Factor 3 Is Regulated by a Dual Phosphorylation-dependent Switch

The Journal of biological chemistry, 2007-08, Vol.282 (31), p.22816-22822

2007

Volltextzugriff (PDF)

Modulation of Kinase Activities In Vitro by Hepatitis C Virus Protease NS3/NS4A Mediated-Cleavage of Key Immune Modulator Kinases

Cells (Basel, Switzerland), 2023-01, Vol.12 (3), p.406

2023

Volltextzugriff (PDF)

IFN-Regulatory Factor 3-Dependent Gene Expression Is Defective in Tbk1-Deficient Mouse Embryonic Fibroblasts

Proceedings of the National Academy of Sciences - PNAS, 2004-01, Vol.101 (1), p.233-238

2004

Volltextzugriff (PDF)

Nucleic Acid Sensors as Therapeutic Targets for Human Disease

Immunity (Cambridge, Mass.), 2020-07, Vol.53 (1), p.78-97

2020

Volltextzugriff (PDF)

MK5 activates Rag transcription via Foxo1 in developing B cells

The Journal of experimental medicine, 2013-07, Vol.210 (8), p.1621-1634

2013

Volltextzugriff (PDF)

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Clinical cancer research, 2022-02, Vol.28 (4), p.677-688

2022

Volltextzugriff (PDF)

NK cells mediate clearance of CD8 + T cell-resistant tumors in response to STING agonists

Science immunology, 2020-03, Vol.5 (45)

2020

Volltextzugriff (PDF)

Gfi1 and gfi1b repress rag transcription in plasmacytoid dendritic cells in vitro

PloS one, 2013-09, Vol.8 (9), p.e75891-e75891

2013

Volltextzugriff (PDF)

Gfi1b negatively regulates Rag expression directly and via the repression of FoxO1

The Journal of experimental medicine, 2012-01, Vol.209 (1), p.187-199

2012

Volltextzugriff (PDF)

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Cell reports (Cambridge), 2018-12, Vol.25 (11), p.3074-3085.e5

2018

Volltextzugriff (PDF)

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I + tumors

Proceedings of the National Academy of Sciences - PNAS, 2022-05, Vol.119 (22), p.e2200568119-e2200568119

2022

Volltextzugriff (PDF)

Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17-Dependent Protection against Mycobacterium tuberculosis Infection

The Journal of immunology (1950), 2022-01, Vol.208 (2), p.407-419

2022

Volltextzugriff (PDF)

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer

JCI insight, 2018-10, Vol.3 (20)

2018

Volltextzugriff (PDF)

Multiple Functions of the IKK-Related Kinase IKKε in Interferon-Mediated Antiviral Immunity

Science (American Association for the Advancement of Science), 2007-03, Vol.315 (5816), p.1274-1278

2007

Volltextzugriff (PDF)

Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Clinical cancer research, 2023-06, Vol.29 (12), p.2336-2336

2023

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(60)

Sprache

Englisch
(59)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The host STING pathway at the interface of cancer and immunity

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

SLC19A1 transports immunoreactive cyclic dinucleotides

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA

Identification of host cytosolic sensors and bacterial factors regulating the type I interferon response to Legionella pneumophila

Induction of type I interferons by bacteria

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

Interferon Regulatory Factor 3 Is Regulated by a Dual Phosphorylation-dependent Switch

Modulation of Kinase Activities In Vitro by Hepatitis C Virus Protease NS3/NS4A Mediated-Cleavage of Key Immune Modulator Kinases

IFN-Regulatory Factor 3-Dependent Gene Expression Is Defective in Tbk1-Deficient Mouse Embryonic Fibroblasts

Nucleic Acid Sensors as Therapeutic Targets for Human Disease

MK5 activates Rag transcription via Foxo1 in developing B cells

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

NK cells mediate clearance of CD8 + T cell-resistant tumors in response to STING agonists

Gfi1 and gfi1b repress rag transcription in plasmacytoid dendritic cells in vitro

Gfi1b negatively regulates Rag expression directly and via the repression of FoxO1

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I + tumors

Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17-Dependent Protection against Mycobacterium tuberculosis Infection

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer

Multiple Functions of the IKK-Related Kinase IKKε in Interferon-Mediated Antiviral Immunity

Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Suchergebnisse filtern